Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
Clinical trial NCT06980454 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06980454
- Sponsor
- Shanghai Henlius Biotech
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-04
- Primary completion
- 2025-12-31
- Enrollment
- 322
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.